AQST Logo

Aquestive Therapeutics, Inc. (AQST) 

NASDAQ
Market Cap
$329.61M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
543 of 960
Rank in Industry
31 of 59

Largest Insider Buys in Sector

AQST Stock Price History Chart

AQST Stock Performance

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with …

Insider Activity of Aquestive Therapeutics, Inc.

Over the last 12 months, insiders at Aquestive Therapeutics, Inc. have bought $0 and sold $429,899 worth of Aquestive Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Aquestive Therapeutics, Inc. have bought $54,873 and sold $951,306 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,000 shares for transaction amount of $4,050 was made by Boyd Peter E. (SVP‑Bus. Process & Info. Tech.) on 2022‑06‑14.

List of Insider Buy and Sell Transactions, Aquestive Therapeutics, Inc.

2024-11-26SaleChief Operating Officer
44
<0.0001%
$4.87$214-20.29%
2024-03-15SaleChief Innovation/Tech Officer
50,000
0.0672%
$6.00$300,000-32.51%
2024-03-08SaleChief Innovation/Tech Officer
25,000
0.0364%
$5.19$129,685-14.96%
2022-06-14PurchaseSVP-Bus. Process & Info. Tech.
5,000
0.0107%
$0.81$4,050+11.38%
2022-06-08PurchaseChief Innovation/Tech Officer
45,871
0.1074%
$0.96$44,036+2.88%
2022-06-08PurchaseSVP-Bus. Process & Info. Tech.
2,293
0.0054%
$0.96$2,201+2.88%
2022-06-08PurchaseGeneral Counsel
13,761
0.0322%
$0.96$13,211+2.88%
2021-02-10Sale
23,460
0.0662%
$6.75$158,355-38.78%
2021-02-09Sale
11,540
0.0328%
$6.75$77,895-38.02%
2021-02-08Sale
40,792
0.1131%
$6.50$265,148-37.03%
2020-08-18Sale
3,000
0.0088%
$8.00$24,000-37.84%
2020-06-04Sale
100,000
0.2958%
$5.11$510,620+2.92%
2020-05-08Sale
80,000
0.2312%
$5.00$400,000+3.69%
2020-04-29Sale
80,000
0.2256%
$4.50$360,000+12.42%
2020-04-27Sale
80,000
0.229%
$4.00$320,000+28.37%
2020-04-14Sale
80,000
0.2445%
$3.85$308,000+42.40%
2020-03-16Purchase
4,000
0.0058%
$0.75$3,000+246.43%
2020-03-16Purchase
28,000
0.0837%
$1.54$43,249+246.43%
2019-08-27Purchase
4,000
0.0166%
$3.99$15,960+14.36%
2019-08-21Purchase
1,800
0.0068%
$3.81$6,858+7.92%

Insider Historical Profitability

1.68%
Schobel Alexander MarkChief Innovation/Tech Officer
984476
1.0797%
$3.6249<0.0001%
Kendall Keith J
638964
0.7008%
$3.6261<0.0001%
BRATTON DOUGLAS K
165000
0.181%
$3.6210
Maxwell John T.
150614
0.1652%
$3.6221<0.0001%
Barber Daniel
101959
0.1118%
$3.6220<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bratton Capital Management L P$41.79M10.789.81M0%+$0100
Vr Adviser Llc$23.67M6.15.56MNew+$23.67M1.15
The Vanguard Group$13.81M3.563.24M+71.65%+$5.77M<0.0001
Franklin Templeton Investments$9.46M2.442.22MNew+$9.46M<0.01
Laurion Capital Management LP$6.58M1.71.55MNew+$6.58M0.05
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.